Table 2 Differences in patients surviving up to 30 days versus 6 months (complete case data)
All patients (n = 3920) | Survivors at 30 days (n = 2293) | Survivors at 6 months (n = 1398) | Deceased at 6 months (n = 1825) | p value | |
|---|---|---|---|---|---|
N [N missing] | 3867 | 2293 | 1398 | 1825 | |
Age [0] | 84 [81–87] | 84 [81–87] | 84 [81–86] | 84 [82–87] | 0.013 |
Gender [0] | 2051 (53%) | 1185 (52%) | 731 (52%) | 1007 (55%) | 0.111 |
IQCODE [922] | 3 [3, 4] | 3 [3, 4] | 3 [3] | 3 [3, 4] | 0 |
Chronic comorbidities [6] | 4 [3–6] | 4 [3–5] | 4 [3–5] | 4 [3–6] | 0.002 |
Drugs daily [7] | 6 [4–9] | 6 [4–9] | 6 [4–8] | 6 [4–9] | 0.04 |
CPS [7] | 10 [7–14] | 10 [7–14] | 10 [7–14] | 11 [7–14] | 0.006 |
CFS 1–3 [17] | 1532 (40%) | 999 (44%) | 658 (47%) | 620 (34%) | < 0.01 |
CFS 4–5 [17] | 1284 (33%) | 795 (35%) | 476 (34%) | 574 (31%) | |
CFS 6–9 [17] | 1034 (27%) | 496 (22%) | 263 (19%) | 616 (34%) | |
Katz [433] | 6 [4–6] | 6 [5, 6] | 6 [5, 6] | 6 [3–6] | < 0.01 |
SOFA [11] | 6 [4–9] | 5 [3–8] | 5 [3–7] | 8 [5–10] | < 0.01 |
Intubated [0] | 1943 (50%) | 932 (41%) | 512 (37%) | 1153 (63%) | < 0.01 |
Tracheostomy [10] | 264 (7%) | 168 (7%) | 65 (5%) | 157 (9%) | < 0.01 |
vasoactive medication [0] | 2326 (60%) | 1169 (51%) | 699 (50%) | 1324 (73%) | < 0.01 |
RRT [0] | 424 (11%) | 163 (7%) | 92 (7%) | 295 (16%) | < 0.01 |
NIV [0] | 881 (23%) | 538 (23%) | 330 (24%) | 400 (22%) | 0.275 |
withhold [0] | 1139 (29%) | 389 (17%) | 222 (16%) | 830 (45%) | < 0.01 |
withdraw [0] | 545 (14%) | 27 (1%) | 13 (1%) | 526 (29%) | < 0.01 |